^
BIOMARKER:
KRAS mutation
i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
A2
KRAS mutation
CRC
cetuximab
Resistant
:
B
KRAS mutation
CRC
trifluridine/tipiracil
Sensitive
:
B
KRAS mutation
NSCLC
pembrolizumab
Sensitive
:
B
KRAS mutation
AML
gilteritinib
Resistant
:
B
KRAS mutation
NSCLC
abemaciclib
Sensitive
:
B
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
B
KRAS mutation
NSCLC
gefitinib
Sensitive
:
B
KRAS mutation
NSCLC
selumetinib
Sensitive
:
B
KRAS mutation
NSCLC
Immunotherapy
Sensitive
:
B
KRAS mutation
NSCLC
nivolumab
Sensitive
:
B
KRAS mutation
CRC
regorafenib
Sensitive
:
B
KRAS mutation
NSCLC
erlotinib
Resistant
:
B
KRAS mutation
NSCLC
pembrolizumab + abemaciclib
Sensitive
:
C2
KRAS mutation
NSCLC
bevacizumab + PCM-075
Sensitive
:
C2
KRAS mutation
NSCLC
trametinib
Sensitive
:
C2
KRAS mutation
LUAD
trametinib
Sensitive
:
C2
KRAS mutation
NSCLC
afatinib + selumetinib
Sensitive
:
C2
KRAS mutation
CRC
sorafenib
Sensitive
:
C2
KRAS mutation
CRC
bevacizumab
Sensitive
:
C2
KRAS mutation
NSCLC
VS-6766
Sensitive
:
C2
KRAS mutation
NSCLC
CYT 387
Sensitive
:
C2
KRAS mutation
NSCLC
sunitinib
Sensitive
:
C2
KRAS mutation
Ovarian Cancer
VS-6766 + VS-6063
Sensitive
:
C2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our